Esperion Therap Inc v. Renata Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Esperion Therapeutics, Inc. (Delaware)
  • Defendant: Renata Limited (Bangladesh); Somerset Therapeutics, LLC (Delaware); Somerset Pharma, LLC (Delaware)
  • Plaintiff's Counsel: Walsh Pizzi Oreilly Falanga LLP
• Case Identification: 2:26-cv-02326, D.N.J., 03/05/2026
• Venue Allegations: Plaintiff alleges venue is proper as to Defendant Renata Limited because it is a foreign corporation not resident in the United States and may be sued in any jurisdiction. Venue is alleged to be proper for Defendants Somerset Therapeutics and Somerset Pharma because their regular and established principal places of business are in New Jersey.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Plaintiff's NEXLIZET® product constitutes an act of infringement of seven U.S. patents.
• Technical Context: The technology concerns pharmaceutical compositions containing bempedoic acid, alone or in combination with ezetimibe, for lowering low-density lipoprotein cholesterol (LDL-C) and treating cardiovascular disease.
• Key Procedural History: This action is brought under the Hatch-Waxman Act, triggered by Defendants' notification to Plaintiff of their ANDA filing with a Paragraph IV certification. The complaint notes this action is related to a consolidated ANDA Litigation, Civil Action No. 2:24-cv-05921, suggesting a broader dispute involving generic versions of Plaintiff's products.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,760,714 - Methods of Making Bempedoic Acid and Compositions of the Same

• Patent Identification: U.S. Patent No. 11760714, titled Methods of Making Bempedoic Acid and Compositions of the Same, issued on September 19, 2023 Compl. ¶39

The Invention Explained

• Problem Addressed: The patent family addresses the technical challenge of developing robust and efficient manufacturing processes for producing bempedoic acid that meets the yield and purity profiles required by regulatory agencies for commercial drug products '511 Patent, col. 1:16-32
• The Patented Solution: The invention is a pharmaceutical composition containing a highly purified crystalline form of bempedoic acid (identified as formula (V)) Compl. ¶77 The solution specified in the patent claims involves achieving a purity level greater than 98% by weight for the active ingredient, while simultaneously controlling for a specific diol impurity (identified as formula (VI)) to a level between 0.0001% and 0.15% Compl. ¶77 The specification details multi-step synthesis and purification methods to achieve this profile '511 Patent, col. 12:33-55 '511 Patent, col. 13:1-19
• Technical Importance: Achieving high purity and strictly controlling specified impurities are critical for the safety, stability, and regulatory approval of pharmaceutical products.

Key Claims at a Glance

• The complaint asserts at least Claim 1 Compl. ¶¶77-81
• The essential elements of independent Claim 1 are:
  • A pharmaceutical composition comprising a pharmaceutical material and a pharmaceutically acceptable excipient.
  • The pharmaceutical material comprises a crystalline form of the compound of formula (V) (bempedoic acid) or a salt thereof.
  • The pharmaceutical material contains the compound of formula (V) in an amount greater than 98% by weight.
  • The pharmaceutical material contains 0.0001% to less than or equal to 0.15% of a compound of formula (VI), an impurity.

U.S. Patent No. 11,613,511 - Methods of Making Bempedoic Acid and Compositions of the Same

• Patent Identification: U.S. Patent No. 11613511, titled Methods of Making Bempedoic Acid and Compositions of the Same, issued on March 28, 2023 Compl. ¶42

The Invention Explained

• Problem Addressed: As with the '714 Patent, this patent addresses the need for high-purity bempedoic acid with a defined impurity profile suitable for a commercial pharmaceutical product '511 Patent, col. 1:16-32
• The Patented Solution: This invention defines a specific crystalline polymorph of bempedoic acid. The solution is a pharmaceutical material with an even higher purity level for bempedoic acid (>99.0%) and the same low level of the formula (VI) impurity, which is further defined by a specific X-ray powder diffraction (XRPD) pattern Compl. ¶90 This XRPD pattern serves as a structural fingerprint for a particular solid-state form of the compound '511 Patent, col. 13:50-67 '511 Patent, col. 16:51-67
• Technical Importance: Controlling the polymorphic form of an active pharmaceutical ingredient is critical because different crystal structures can affect a drug's solubility, stability, and bioavailability.

Key Claims at a Glance

• The complaint asserts at least Claim 1 Compl. ¶¶90-94
• The essential elements of independent Claim 1 are:
  • A pharmaceutical material comprising a crystalline form of the compound of formula (V) (bempedoic acid) or a salt thereof.
  • The material contains the compound of formula (V) in an amount greater than 99.0% by weight.
  • The material contains 0.0001% to less than or equal to 0.15% of a compound of formula (VI).
  • The crystalline form exhibits an XRPD pattern with peaks at specific diffraction angles (2θ), including 10.3±0.2, 10.4±0.2, and 17.9±0.2, among others.

Multi-Patent Capsules

• Patent Identification: U.S. Patent No. 11926584, titled Methods of Making Bempedoic Acid and Compositions of the Same, issued March 12, 2024 Compl. ¶45

  • Technology Synopsis: This patent claims a method of medical treatment. It is directed to a method of lowering LDL-C in a human by administering a therapeutically effective amount of a pharmaceutical material containing a crystalline form of bempedoic acid with a specified high purity (>99.0%) and a low, defined range of a specific impurity (formula (VI)) Compl. ¶102
  • Asserted Claims: At least Claim 1 (Compl. ¶102; Compl. ¶103; Compl. ¶104; Compl. ¶105; Compl. ¶106).
  • Accused Features: The administration of the Renata ANDA Product by patients and medical practitioners, as instructed by its proposed package insert, is alleged to infringe Compl. ¶¶108-111

• Patent Identification: U.S. Patent No. 11744816, titled Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease, issued September 5, 2023 Compl. ¶48

  • Technology Synopsis: This patent claims a method of treatment for a specific patient population. It is directed to a method of lowering LDL-C by administering 180 mg of bempedoic acid and 10 mg of ezetimibe to a subject who has familial hypercholesterolemia Compl. ¶120
  • Asserted Claims: At least Claim 1 (Compl. ¶120; Compl. ¶121; Compl. ¶122; Compl. ¶123; Compl. ¶124; Compl. ¶125).
  • Accused Features: The Renata ANDA Product is alleged to contain 180 mg of bempedoic acid and 10 mg of ezetimibe Compl. ¶121 The proposed package insert is alleged to instruct administration for an infringing use Compl. ¶129

• Patent Identification: U.S. Patent No. 12398087, titled Methods of Making Bempedoic Acid and Compositions of the Same, issued August 26, 2025 Compl. ¶51

  • Technology Synopsis: This patent claims a pharmaceutical material with a specific purity profile. It is directed to a composition comprising bempedoic acid at a purity greater than 98% and containing a specific diol impurity (formula (VI)) within a different range (0.001% to 0.15%) than the '714 Patent Compl. ¶138
  • Asserted Claims: At least Claim 1 (Compl. ¶138; Compl. ¶139; Compl. ¶140; Compl. ¶141; Compl. ¶142).
  • Accused Features: Defendants' ANDA Product is alleged to be a pharmaceutical material meeting these specific purity and impurity limitations Compl. ¶142

• Patent Identification: U.S. Patent No. 12404227, titled Methods of Making Bempedoic Acid and Compositions of the Same, issued September 2, 2025 Compl. ¶54

  • Technology Synopsis: This patent claims a pharmaceutical material with a different impurity profile. It is directed to a composition comprising bempedoic acid at a purity greater than 99.0% and containing a different, acetate impurity (formula (VIII)) within a specific range (0.0001% to 0.15%) Compl. ¶151
  • Asserted Claims: At least Claim 1 (Compl. ¶151; Compl. ¶152; Compl. ¶153; Compl. ¶154; Compl. ¶155).
  • Accused Features: Defendants' ANDA Product is alleged to be a pharmaceutical material meeting these specific purity and impurity limitations Compl. ¶155

• Patent Identification: U.S. Patent No. 10912751, titled Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease, issued February 9, 2021 Compl. ¶57

  • Technology Synopsis: This patent claims a method of treatment using a specific fixed-dose combination. It is directed to a method of treating familial hypercholesterolemia by administering a fixed 180 mg dose of bempedoic acid and a fixed 10 mg dose of ezetimibe Compl. ¶164
  • Asserted Claims: At least Claim 1 (Compl. ¶164; Compl. ¶165; Compl. ¶166; Compl. ¶167; Compl. ¶168).
  • Accused Features: The Renata ANDA Product is alleged to be a fixed-dose combination of 180 mg bempedoic acid and 10 mg ezetimibe, and its proposed package insert is alleged to instruct its administration for the claimed treatment (Compl. ¶¶165; Compl. ¶172).

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is the "Renata ANDA Product," a proposed generic version of NEXLIZET® for which Defendants have submitted ANDA No. 221169 to the FDA for approval Compl. ¶15

Functionality and Market Context

• NEXLIZET® is a combination of bempedoic acid, an ACL inhibitor, and ezetimibe, a cholesterol absorption inhibitor, used to reduce LDL-C in adults with primary hyperlipidemia Compl. ¶63 The complaint presents the chemical structure of bempedoic acid, the primary active ingredient Compl. ¶64 The Renata ANDA Product has been represented to the FDA as having the same active ingredient, dosage form, and strength as NEXLIZET®, and as being bioequivalent to it Compl. ¶70
• Defendants are alleged to be seeking approval to manufacture and sell this generic version prior to the expiration of the patents-in-suit Compl. ¶15 The submission of the ANDA itself constitutes the act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶78

IV. Analysis of Infringement Allegations

11,760,714 Patent Infringement Allegations

11,613,511 Patent Infringement Allegations

Identified Points of Contention

• Evidentiary Questions: The complaint was filed before Plaintiff received access to the ANDA Compl. ¶74 Therefore, the central dispute will be factual and evidentiary: does the proposed Renata ANDA Product, as described in its confidential ANDA submission, actually meet the specific purity, impurity, and (for the '511 patent) polymorphic limitations recited in the asserted claims? The complaint alleges infringement "upon information and belief" Compl. ¶81, which will require substantiation through discovery of the ANDA.
• Technical Questions: For the '511 Patent, a key technical question will be whether the crystalline form of bempedoic acid used in the Renata ANDA Product produces an XRPD pattern that falls within the scope of the claimed peaks. This may involve disputes over analytical testing methods, instrument calibration, and the interpretation of peak data, including the ±0.2 margin.

V. Key Claim Terms for Construction

• The Term: "crystalline form"
• Context and Importance: This term appears in the preambles of the independent claims of both the '714 and '511 patents Compl. ¶77 Compl. ¶90 Its construction is important because infringement may depend on whether Defendants' proposed product contains bempedoic acid in a "crystalline" state, as opposed to an amorphous or semi-crystalline state. Practitioners may focus on this term because polymorphic and solid-state characteristics are often a central battleground in pharmaceutical patent litigation.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term itself is not explicitly defined in the patent specification. A party could argue that, absent a limiting definition, it should be given its plain and ordinary meaning, which would encompass any solid material with a regular, repeating atomic structure, not limited to a specific polymorph unless further specified in the claim body.
  • Evidence for a Narrower Interpretation: The specification of the '511 patent family provides detailed characterization data for a specific crystalline form, including XRPD data, melting point, and other analytics '511 Patent, col. 16:47-67 '511 Patent, col. 17:1-25 '511 Patent, FIG. 4 A party could argue that these specific disclosures define and limit the scope of "crystalline form" to the particular polymorphs disclosed in the patent, especially for the '511 patent, which explicitly claims an XRPD pattern.

VI. Other Allegations

• Indirect Infringement: The complaint alleges inducement of and contribution to infringement for the asserted method patents ('584, '816, and '751 patents) Compl. ¶105 Compl. ¶124 Compl. ¶167 The allegations are based on the claim that Defendants' ANDA includes a proposed package insert with directions that will instruct and encourage medical practitioners and patients to administer the Renata ANDA Product in a manner that directly infringes the method claims Compl. ¶108 Compl. ¶127 Compl. ¶170
• Willful Infringement: The complaint does not explicitly use the term "willful infringement." However, it lays the groundwork for such a claim by alleging that Defendants had knowledge of the patents-in-suit at least as of the time they submitted the ANDA, citing the patents' listing in the FDA's Orange Book and their identification in the ANDA Notice Letter Compl. ¶72 Compl. ¶95 Compl. ¶113 Compl. ¶131 Compl. ¶143 Compl. ¶156 Compl. ¶174 The prayer for relief requests a declaration that this is an "exceptional case" and an award of attorneys' fees, which is often associated with findings of willful infringement or other litigation misconduct Compl. ¶186

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of analytical proof: Does the "Renata ANDA Product," as detailed in the confidential ANDA submission, contain a crystalline form of bempedoic acid that meets the specific, quantitative purity (>98% or >99%) and impurity (<0.15% of specific compounds) limitations of the asserted composition claims?
• A key technical question for the '511 patent will be one of structural identity: Does the bempedoic acid in the accused product exhibit the specific X-ray powder diffraction pattern claimed, thereby matching the patented polymorph, or is there a crystallographic difference that could support a non-infringement argument?
• For the method claims, a primary question will be one of induced infringement: Will the final, FDA-approved label for the Renata ANDA Product instruct or encourage medical professionals and patients to administer the drug for the specific indications claimed in the '584, '816, and '751 patents, such as treating familial hypercholesterolemia?